Search

Your search keyword '"Lonardi, Carolina"' showing total 22 results
Start Over Author "Lonardi, Carolina" Publication Type Academic Journals
22 results on '"Lonardi, Carolina"'

1. Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Author

Yong, Kwee, Einsele, Hermann, Schecter, Jordan M., Roccia, Tito, Deraedt, William, Lendvai, Nikoletta, Slaughter, Ana, Lonardi, Carolina, Connors, Kaitlyn, Qi, Keqin, Londhe, Anil, Carson, Robin, Kharat, Akshay, Cost, Patricia, Valluri, Satish, Mendes, João, Pacaud, Lida, Patel, Nitin, Florendo, Erika, and Dhakal, Binod

Published
2025
Full Text
View/download PDF

3. Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Author

Dhakal, Binod, Einsele, Hermann, Schecter, Jordan M, Roccia, Tito, Deraedt, William, Lendvai, Nikoletta, Slaughter, Ana, Lonardi, Carolina, Connors, Kaitlyn, Qi, Keqin, Londhe, Anil, Carson, Robin, Voelker, Jennifer, Cost, Patricia, Valluri, Satish, Florendo, Erika, Pacaud, Lida, and Yong, Kwee

Published
2022
Full Text
View/download PDF

4. MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

Author

Mina, Roberto, Dhakal, Binod, San-Miguel, Jesus, Kwon, Mi, Purtill, Duncan, Magen, Hila, Dutka, Magdalena, Delforge, Michel, Vij, Ravi, Wichert, Stina, Yoon, Sung-Soo, Minnema, Monique C., Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Vogel, Martin, Li, Katherine, Chen, Diana, Zhao, Man, Yeh, Tzu-min, Benachour, Nina, Lengil, Tamar, Koneru, Mythili, Patel, Nitin, Florendo, Erika, Costa Filho, Octavio, Einsele, Hermann, Manier, Salomon, and Martinez-Lopez, Joaquin

Published
2024
Full Text
View/download PDF

5. MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis

Author

Costa, Luciano, Weisel, Katja, van de Donk, Niels WCJ, Sidana, Surbhi, Cohen, Yaël, Purtill, Duncan, Touzeau, Cyrille, Fernández de Larrea, Carlos, Martinez-Lopez, Joaquin, Lendvai, Nikoletta, Slaughter, Ana, Lonardi, Carolina, Zhao, Man, Li, Katherine, Vogel, Martin, Koneru, Mythili, Patel, Nitin, Florendo, Erika, Costa Filho, Octavio, and Victoria, Maria-Victoria

Published
2024
Full Text
View/download PDF

6. MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

Author

Lin, Yi, Leleu, Xavier, Gatt, Moshe, Karlin, Lionel, Spencer, Andrew, Iida, Shinsuke, Ishida, Tadao, Anguille, Sébastien, Ki, Chang-Ki, Jin Kim, Seok, Slaughter, Ana, Lonardi, Carolina, Benachour, Nina, Vogel, Martin, Lendvai, Nikoletta, Plaks, Vicki, Li, Katherine, Chen, Diana, Li, Quanlin, Lengil, Tamar, Koneru, Mythili, Patel, Nitin, Costa Filho, Octavio, Harrison, Simon J., San-Miguel, Jesús, and Einsele, Hermann

Published
2024
Full Text
View/download PDF

7. Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

Author

Mina, Roberto, Dhakal, Binod, San-Miguel, Jesus, Kwon, Mi, Purtill, Duncan, Magen, Hila, Dutka, Magdalena, Delforge, Michel, Vij, Ravi, Wichert, Stina, Yoon, Sung-Soo, Minnema, Monique C., Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Vogel, Martin, Li, Katherine, Chen, Diana, Zhao, Man, Yeh, Tzu-min, Benachour, Nina, Lengil, Tamar, Koneru, Mythili, Patel, Nitin, Florendo, Erika, Costa Filho, Octavio, Einsele, Hermann, Manier, Salomon, and Martinez-Lopez, Joaquin

Published
2024
Full Text
View/download PDF

8. Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis

Author

Costa, Luciano, Weisel, Katja, WCJ van de Donk, Niels, Sidana, Surbhi, Cohen, Yaël, Purtill, Duncan, Touzeau, Cyrille, Fernández de Larrea, Carlos, Martinez-Lopez, Joaquin, Lendvai, Nikoletta, Slaughter, Ana, Lonardi, Carolina, Zhao, Man, Li, Katherine, Vogel, Martin, Koneru, Mythili, Patel, Nitin, Florendo, Erika, Costa Filho, Octavio, and Mateos, Maria-Victoria

Published
2024
Full Text
View/download PDF

9. Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

Author

Lin, Yi, Leleu, Xavier, Gatt, Moshe, Karlin, Lionel, Spencer, Andrew, Iida, Shinsuke, Ishida, Tadao, Anguille, Sébastien, Min, Chang-Ki, Jin Kim, Seok, Slaughter, Ana, Lonardi, Carolina, Benachour, Nina, Vogel, Martin, Lendvai, Nikoletta, Plaks, Vicki, Li, Katherine, Chen, Diana, Li, Quanlin, Lengil, Tamar, Koneru, Mythili, Patel, Nitin, Costa Filho, Octavio, Harrison, Simon J., San-Miguel, Jesús, and Einsele, Hermann

Published
2024
Full Text
View/download PDF

10. Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Author

van de Donk, Niels W.C.J., Sidana, Surbhi, Schecter, Jordan M, Jackson, Carolyn C, Lendvai, Nikoletta, De Braganca, Kevin C., Slaughter, Ana, Lonardi, Carolina, Vlummens, Philip, Varsos, Helen, Corsale, Christina, Madduri, Deepu, Jadidi, Shirin, Gu, Junchen, Zhao, Hao, Li, Katherine, Lee, Erin, Marquez, Loreta, Zhao, Man, Yeh, Tzu-min, Chen, Diana, Florendo, Erika, Patel, Nitin, Akram, Muhammad, Perez-Larraya, Jaime Gallego, and Rodriquez-Otero, Paula

Published
2024
Full Text
View/download PDF

11. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 Trial

Author

Sidiqi, M Hasib, Corradini, Paolo, Purtill, Duncan, Einsele, Hermann, Dhakal, Binod, Karlin, Lionel, Manier, Salomon, Iida, Shinsuke, Giebel, Sebastian, Harrison, Simon J, Lipe, Brea, Khan, Dr. Abdullah Mohammad, Schecter, Jordan M, Jackson, Carolyn C, Yeh, Tzu-min, Banerjee, Arnob, Deraedt, William, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Li, Katherine, Chen, Diana, Gilbert, Jane, Roccia, Tito, Zhao, Man, Patel, Nitin, Florendo, Erika, Koneru, Mythili, Filho, Octavio Costa, Geng, Dong, San-Miguel, Jesús, and Yong, Kwee

Published
2024
Full Text
View/download PDF

12. Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Author

Van De Donk, Niels W.C.J., Sidana, Surbhi, Schecter, Jordan M., Jackson, Carolyn Chang, Lendvai, Nikoletta, De Braganca, Kevin C, Slaughter, Ana, Lonardi, Carolina, Vlummens, Philip, Varsos, Helen, Corsale, Christina, Madduri, Deepu, Jadidi, Shirin, Gu, Junchen, Zhao, Hao, Li, Katherine, Lee, Erin, Marquez, Loreta, Zhao, Man, Yeh, Tzu-min, Chen, Diana, Florendo, Erika, Patel, Nitin, Akram, Muhammad, Gellego Perez-Larraya, Jaime, and Rodriguez Otero, Paula

Published
2023
Full Text
View/download PDF

13. Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Author

Sidiqi, M Hasib, Corradini, Paolo, Purtill, Duncan, Einsele, Hermann, Dhakal, Binod, Karlin, Lionel, Manier, Salomon, Iida, Shinsuke, Giebel, Sebastian, Harrison, Simon J., Lipe, Brea, Khan, Abdullah, Schecter, Jordan M., Jackson, Carolyn Chang, Yeh, Tzu-min, Banerjee, Arnob, Deraedt, William, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Li, Katherine, Chen, Diana, Gilbert, Jane, Roccia, Tito, Zhao, Man, Patel, Nitin, Florendo, Erika, Koneru, Mythili, Costa Filho, Octavio, Geng, Dong, San Miguel, Jesus, and Yong, Kwee

Published
2023
Full Text
View/download PDF

14. CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Author

Harrison, Simon J., Nguyen, Tamia, Rahman, Marzia, Er, Jeremy, Li, Jessica, Li, Katherine, Lendvai, Nikoletta, Schecter, Jordan M., Banerjee, Arnob, Roccia, Tito, Foulk, Brad, Gu, Junchen, Zhao, Hao, Smirnov, Denis, Slaughter, Ana, Lonardi, Carolina, Lee, Erin, Marquez, Loreta, Jadidi, Shirin, Costa Filho, Octavio, Patel, Nitin, Geng, Dong, Haynes, Nicole M, Kelly, Hannah, Lade, Stephen, Grimmond, Sean, and Blombery, Piers

Published
2023
Full Text
View/download PDF

15. Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Author

Mina, Roberto, Mylin, Anne K, Yokoyama, Hisayuki, Magen, Hila, Alsdorf, Winfried, Minnema, Monique C, Shune, Leyla, Isufi, Iris, Harrison, Simon J., Shah, Urvi A, Schecter, Jordan M., Lendvai, Nikoletta, Gries, Katharine S, Katz, Eva G, Slaughter, Ana, Lonardi, Carolina, Gilbert, Jane, Li, Quanlin, Deraedt, William, Costa Filho, Octavio, Patel, Nitin, Karlin, Lionel, and Weisel, Katja

Published
2023
Full Text
View/download PDF

16. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial

Author

de Larrea, Carlos Fernández, Harrison, Simon, Martinez-Lopez, Joaquín, Mateos, Maria-Victoria, Oriol, Albert, van de Donk, Niels, Purtill, Duncan, Benjamin, Reuben, Cavo, Michele, Corradini, Paolo, Dytfeld, Dominik, Li, Katherine, Banerjee, Arnob, Chang, Shirley Shih-Yu, Jaiprasart, Pharavee, Slaughter, Ana, Lonardi, Carolina, Schecter, Jordan, Deraedt, William, Chen, Diana, Yeh, Tzu-min, Patel, Nitin, Geng, Dong, Min, Chang-Ki, and Strouse, Christopher

Published
2023
Full Text
View/download PDF

17. OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy

Author

Manier, Salomon, San-Miguel, Jesús, Dhakal, Binod, Yong, Kwee, Martinez-Lopez, Joaquín, Oriol, Albert, Purtill, Duncan, Sidiqi, Hasib, Iida, Shinsuke, Mylin, Anne, Mina, Roberto, Karlin, Lionel, Deraedt, William, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Schecter, Jordan, Li, Katherine, Chen, Diana, Gilbert, Jane, Yeh, Tzu-min, Florendo, Erika, Pacaud, Lida, Patel, Nitin, and Einsele, Hermann

Published
2023
Full Text
View/download PDF

20. S100: FIRST PHASE 3 RESULTS FROM CARTITUDE‐4: CILTA‐CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE‐REFRACTORY MULTIPLE MYELOMA.

Author

Einsele, Hermann, Yong, Kwee, Harrison, Simon, Mateos, Maria‐Victoria, Moreau, Philippe, van de Donk, Niels W.C.J., Sidana, Surbhi, Popat, Rakesh, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Schecter, Jordan, LI, Katherine, Zudaire, Enrique, Chen, Diana, Gilbert, Jane, Yeh, Tzu‐Min, Pacaud, Lida, Patel, Nitin, and Dhakal, Binod

Published
2023
Full Text
View/download PDF

21. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

Author

Dhakal, Binod, Yong, Kwee, Harrison, Simon J., Mateos, Maria-Victoria, Moreau, Philippe, van de Donk, Niels W.C.J., Sidana, Surbhi, Popat, Rakesh, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Schecter, Jordan Mark, Li, Katherine, Zudaire, Enrique, Chen, Ying, Gilbert, Jane, Bubuteishvili-Pacaud, Lida, Patel, Nitin, San-Miguel, Jesús, and Einsele, Hermann

Published
2023
Full Text
View/download PDF

22. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

Author

San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, and Einsele H

Subjects
Humans, Lenalidomide adverse effects, Neurotoxicity Syndromes, Progression-Free Survival, Drug Resistance, Neoplasm, Multiple Myeloma drug therapy, Multiple Myeloma mortality, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods, Antineoplastic Agents, Immunological therapeutic use
Abstract

Background: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease., Methods: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival., Results: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%)., Conclusions: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.)., (Copyright © 2023 Massachusetts Medical Society.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results